• Oncology Conference Insight: ASH 2016 --- Immunotherapies such as checkpoint inhibitors have had a dramatic impact on treatment paradigms for many tumor types over the past few years, and their full potential is far from being realized. Hot on the heels of checkpoint inhibitors are engineered, adoptive T-cell therapies that represent another promising advancement.
  • GALLIUM turns Gazyva into gold in NHL

    by Jay Grisolano  |  Dec 5, 2016
    Oncology Conference Insight: ASH 2016 --- In the management of non-Hodgkin lymphoma (NHL), Rituxan-based therapy forms the foundation for therapy in all settings. This holds true for most subtypes of NHL, including follicular lymphoma, mantle cell lymphoma, and diffuse B-cell lymphoma. While Rituxan-based therapy is highly effective and leads to improvement in survival rates, patients are rarely cured, and relapse is common, occurring in about 20-30% of patients.
  • On December 1, we mark World AIDS Day, which was created by WHO in partnership with the United Nations (UN) to raise awareness on disease prevention as well as fight the prejudice and stigmas that people living with HIV and AIDS have to cope with.
  • It’s lobbying, Jim, but not as we know it

    by Mark Sales  |  Nov 16, 2016
    Reputation is something that has always been close to our hearts in healthcare, an industry often derided by many (including my non-pharma friends) as “evil,” yet the numbers tell a different story.
  • Market forces continue to drive oncology practices to align, invest and adapt to capture patient volume, adjust to decreasing payer reimbursement, optimize revenue, and reduce financial risk.
More than one Google Analytics scripts are registered. Please verify your pages and templates.